Affiliation:
1. Department of Pharmacokinetics & Pharmacodynamics, Gause Institute of New Antibiotics
2. Institute of Normal Physiology, Russian Academy of Medical Sciences, Moscow, Russia
3. Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts
Abstract
ABSTRACT
Prediction of the relative efficacies of different fluoroquinolones is often based on the ratios of the clinically achievable area under the concentration-time curve (AUC) to the MIC, usually with incorporation of the MIC
50
or the MIC
90
and with the assumption of antibiotic-independent patterns of the AUC/MIC-response relationships. To ascertain whether this assumption is correct, the pharmacodynamics of seven pharmacokinetically different quinolones against two clinical isolates of
Staphylococcus aureus
were studied by using an in vitro model. Two differentially susceptible clinical isolates of
S. aureus
were exposed to two 12-h doses of ciprofloxacin (CIP) and one dose of gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), levofloxacin (LVX), moxifloxacin (MXF), and trovafloxacin (TVA) over similar AUC/MIC ranges from 58 to 932 h. A specific bacterial strain-independent AUC/MIC relationship with the antimicrobial effect (
I
E
) was associated with each quinolone. Based on the
I
E
-log AUC/MIC relationships, breakpoints (BPs) that are equivalent to a CIP AUC/MIC ratio of 125 h were predicted for GRX, MXF, and TVA (75 to 78 h), GAT and GEM (95 to 103 h) and LVX (115 h). With GRX and LVX, the predicted BPs were close to those established in clinical settings (no clinical data on other quinolones are available in the literature). To determine if the predicted AUC/MIC BPs are achievable at clinical doses, i.e., at the therapeutic AUCs (AUC
ther
s), the AUC
ther
/MIC
50
ratios were studied. These ratios exceeded the BPs for GAT, GEM, GRX, MXF, TVA, and LVX (750 mg) but not for CIP and LVX (500 mg). AUC/MIC ratios above the BPs can be considered of therapeutic potential for the quinolones. The highest ratios of AUC
ther
/MIC
50
to BP were achieved with TVA, MXF, and GEM (2.5 to 3.0); intermediate ratios (1.5 to 1.6) were achieved with GAT and GRX; and minimal ratios (0.3 to 1.2) were achieved with CIP and LVX.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference50 articles.
1. Adam, B. 1998. Comparative in vitro activity of grepafloxacin against fresh bacterial isolates from paediatric patients. Antiinfect. Drug Chemother.16:70.
2. Pharmacokinetics and Tolerability of Gemifloxacin (SB-265805) after Administration of Single Oral Doses to Healthy Volunteers
3. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother.40:639-651.
4. Bergan, T., and S. B. Thorsteinsson. 1986. Pharmacokinetics and bioavailability of ciprofloxacin, p. 111-121, Proceedings of the First International Ciprofloxacin Workshop, 1985, vol. 34. Elsevier Science Publishers B.V. (Excerpta Medica), Amsterdam, The Netherlands.
5. Bergan, T., S. B. Thorsteinsson, R. Solberg, L. Bjornskau, I. M. Kolstad, and S. Johnsen. 1987. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am. J. Med.82:97-102.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献